our current active studies

• Sponsor: Cerevance
• General Summary of Trial: Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications
• Study Drug: Adjunctive therapy, a non-Dopaminergic, G-Protein Coupled Receptor (GPR6), inverse agonist also called, Solengepras. It’s a tablet that is orally administered every day.
• Looking to target: Patients with PD that experience OFF periods/motor complications.
• Length 16-21 weeks of participation
• 30 y/o , no DBS patients

• Sponsor: Amneal
• General Summary: Phase 4 Study IPX203-401-23 is designed as an open-label, multi-center Phase 4 study to evaluate the efficacy and safety of CREXONT under real world conditions in patients with PD, who will be treated as appropriate for their condition and guided by the United States (US) FDA approved CREXONT Prescribing Information. 
• Study Product: Carbidopa-Levodopa Extended-Release Capsules orally administered. 
• Target Population: Patients with moderately severe PD patients who experience motor complications, such as dyskinesias and OFF period episodes of at least 2.5hrs/day
• Length: 13-14 months 
• Patients who have done Deep brain stimulation (DBS) are excluded from this trial.

• Sponsor: AbbVie
• General Summary: A Global Real-World Evidence Study on the long-term effectiveness of ABBV-951 in Advanced Parkinson´s Disease in routine clinical practice (ROSSINI: Real-world Outcomes with continuous Subcutaneous levodopa Infusion)
• Study Product: Continuous SC Apomorphine Infusion, administering Levadopa
• Targeting: Pts with advanced PD, that experience motor complications/OFF periods and dyskinesia everyday
• 18 y/o or older, DBS patients are welcome
• Length: 3+ years
   

 This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and older with Parkinson's disease and Parkinsonism with 2 years of follow-up. A total of 3,500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging. For more details go here.